{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:25:43Z","timestamp":1787160343096,"version":"build-2736575974"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalimaging.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Imaging"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.clinimag.2022.09.004","type":"journal-article","created":{"date-parts":[[2022,9,24]],"date-time":"2022-09-24T20:37:07Z","timestamp":1664051827000},"page":"25-31","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["18F-FDG PET\/CT prognostic role in predicting response to salvage therapy in relapsed\/refractory Hodgkin's lymphoma"],"prefix":"10.1016","volume":"92","author":[{"given":"Roya","family":"Eisazadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2271-9764","authenticated-orcid":false,"given":"Seyed Ali","family":"Mirshahvalad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.clinimag.2022.09.004_bb0005","first-page":"116","article-title":"Lymphoma: a review and update on recent progress","volume":"68","author":"Shanbhag","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.clinimag.2022.09.004_bb0010","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/nrc2542","article-title":"The biology of Hodgkin's lymphoma","volume":"9","author":"K\u00fcppers","year":"2009","journal-title":"Nat Rev Cancer"},{"issue":"20","key":"10.1016\/j.clinimag.2022.09.004_bb0015","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clinimag.2022.09.004_bb0020","series-title":"Hodgkin Lymphoma: Diagnosis and Treatment","first-page":"1574","author":"Ansell","year":"2015"},{"issue":"8","key":"10.1016\/j.clinimag.2022.09.004_bb0025","first-page":"1326","article-title":"The role of PET in lymphoma","volume":"47","author":"Jhanwar","year":"2006","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1016\/j.clinimag.2022.09.004_bb0030","doi-asserted-by":"crossref","first-page":"W91","DOI":"10.2214\/AJR.09.2637","article-title":"Clinical utility of PET\/CT in lymphoma","volume":"194","author":"Cronin","year":"2010","journal-title":"Am J Roentgenol"},{"issue":"1","key":"10.1016\/j.clinimag.2022.09.004_bb0035","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2967\/jnumed.109.067892","article-title":"18F-FDG avidity in lymphoma readdressed: a study of 766 patients","volume":"51","author":"Weiler-Sagie","year":"2010","journal-title":"J Nucl Med"},{"issue":"10","key":"10.1016\/j.clinimag.2022.09.004_bb0040","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s12149-011-0549-0","article-title":"Impact of FDG-PET\/CT in the management of lymphoma","volume":"25","author":"Baba","year":"2011","journal-title":"Ann Nucl Med"},{"issue":"1","key":"10.1016\/j.clinimag.2022.09.004_bb0045","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1148\/rg.301095088","article-title":"FDG PET\/CT of extranodal involvement in non-Hodgkin lymphoma and Hodgkin disease","volume":"30","author":"Paes","year":"2010","journal-title":"Radiographics"},{"issue":"4","key":"10.1016\/j.clinimag.2022.09.004_bb0050","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/joim.12813","article-title":"FDG-PET\/CT in the management of lymphomas: current status and future directions","volume":"284","author":"El-Galaly","year":"2018","journal-title":"J Intern Med"},{"issue":"2","key":"10.1016\/j.clinimag.2022.09.004_bb0055","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1148\/radiol.2015142088","article-title":"Imaging for staging and response assessment in lymphoma","volume":"276","author":"Johnson","year":"2015","journal-title":"Radiology"},{"issue":"27","key":"10.1016\/j.clinimag.2022.09.004_bb0060","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"27","key":"10.1016\/j.clinimag.2022.09.004_bb0065","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","article-title":"Roleof imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group","volume":"32","author":"Barrington","year":"2014","journal-title":"Journal of clinical oncology"},{"issue":"15","key":"10.1016\/j.clinimag.2022.09.004_bb0070","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1182\/blood-2017-09-772632","article-title":"Biology of classical hodgkin lymphoma: implications for prognosis and novel therapies","volume":"131","author":"Mottok","year":"2018","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.clinimag.2022.09.004_bb0075","doi-asserted-by":"crossref","first-page":"e559","DOI":"10.1097\/RLU.0000000000002732","article-title":"Prognostic value of pretreatment radiomic features of 18F-FDG PET in patients with Hodgkin lymphoma","volume":"44","author":"Lue","year":"2019","journal-title":"Clin Nucl Med"},{"issue":"1","key":"10.1016\/j.clinimag.2022.09.004_bb0080","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0210224","article-title":"Prognostic value of baseline metabolic tumor volume and total lesion glycolysis in patients with lymphoma: a meta-analysis","volume":"14","author":"Guo","year":"2019","journal-title":"PloS one"},{"issue":"1","key":"10.1016\/j.clinimag.2022.09.004_bb0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-018-37197-z","article-title":"A PET radiomics model to predict refractory mediastinal Hodgkin lymphoma","volume":"9","author":"Milgrom","year":"2019","journal-title":"Sci Rep"},{"issue":"20","key":"10.1016\/j.clinimag.2022.09.004_bb0090","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1182\/blood-2017-06-788877","article-title":"Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma","volume":"130","author":"Moskowitz","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clinimag.2022.09.004_bb0095","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ctrv.2019.06.002","article-title":"The role of PET\/CT in the modern treatment of Hodgkin lymphoma","volume":"77","author":"Zaucha","year":"2019","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"10.1016\/j.clinimag.2022.09.004_bb0100","first-page":"272","article-title":"Baseline total lesion glycolysis measured with 18F-FDG PET\/CT as a predictor of progression-free survival in diffuse large B-cell lymphoma: a pilot study","volume":"3","author":"Esfahani","year":"2013","journal-title":"Am J Nucl Med Molec Imaging"},{"issue":"7","key":"10.1016\/j.clinimag.2022.09.004_bb0105","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.2967\/jnumed.112.116053","article-title":"Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis measured by 18F-FDG PET\/CT in salivary gland carcinomas","volume":"54","author":"Ryu","year":"2013","journal-title":"J Nucl Med"},{"issue":"5","key":"10.1016\/j.clinimag.2022.09.004_bb0110","doi-asserted-by":"crossref","first-page":"709","DOI":"10.2967\/jnumed.111.099531","article-title":"18F-FDG metabolic tumor volume and total glycolytic activity of oral cavity and oropharyngeal squamous cell cancer: adding value to clinical staging","volume":"53","author":"Dibble","year":"2012","journal-title":"J Nucl Med"},{"issue":"5","key":"10.1016\/j.clinimag.2022.09.004_bb0115","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s00277-016-2619-9","article-title":"Prognostic value of pretransplant FDG-PET in refractory\/relapsed hodgkin lymphoma treated with autologous stem cell transplantation: systematic review and meta-analysis","volume":"95","author":"Adams","year":"2016","journal-title":"Ann Hematol"},{"issue":"7","key":"10.1016\/j.clinimag.2022.09.004_bb0120","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1093\/annonc\/mdn768","article-title":"FDG-PET for assessment of early treatment response after four cycles of chemotherapy in patients with advanced-stage Hodgkin's lymphoma has a high negative predictive value","volume":"20","author":"Markova","year":"2009","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.clinimag.2022.09.004_bb0125","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1182\/blood-2002-12-3842","article-title":"Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation","volume":"102","author":"Spaepen","year":"2003","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.clinimag.2022.09.004_bb0130","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1038\/bmt.2013.88","article-title":"Pre-transplant FDG-PET-based survival model in relapsed and refractory Hodgkin's lymphoma: outcome after high-dose chemotherapy and auto-SCT","volume":"48","author":"Akhtar","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.clinimag.2022.09.004_bb0135","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.hoc.2013.10.008","article-title":"FDG-PET response-adapted therapy: Is 18f-fluorodeoxyglucose positron emission tomography a safe predictor for a change of therapy? Review","volume":"28","author":"Hutchings","year":"2014","journal-title":"Hematol Oncol Clin North Am"},{"issue":"7","key":"10.1016\/j.clinimag.2022.09.004_bb0140","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1182\/blood-2011-10-388058","article-title":"Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with hodgkin lymphoma","volume":"119","author":"Moskowitz","year":"2012","journal-title":"Blood."},{"issue":"11","key":"10.1016\/j.clinimag.2022.09.004_bb0145","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/j.bbmt.2011.04.011","article-title":"Prognostic significance of FDG-PET in relapsed or refractory classical hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantation","volume":"17","author":"Smeltzer","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.clinimag.2022.09.004_bb0150","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1007\/s00277-020-04039-w","article-title":"Prognostic role of baseline 18F-FDG PET\/CT metabolic parameters in elderly HL: a two-center experience in 123 patients","volume":"99","author":"Albano","year":"2020","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clinimag.2022.09.004_bb0155","first-page":"11","article-title":"Frontline therapy for classical hodgkin lymphoma by stage and prognostic factors. Review","author":"Allen","year":"2017","journal-title":"Clin Med Insights: Oncol"},{"issue":"8","key":"10.1016\/j.clinimag.2022.09.004_bb0160","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1007\/s12149-016-1092-9","article-title":"Interim FDG-PET\/CT in hodgkin lymphoma: the prognostic role of the ratio between target lesion and liver SUVmax (rPET)","volume":"30","author":"Annunziata","year":"2016","journal-title":"Ann Nucl Med"},{"issue":"9","key":"10.1016\/j.clinimag.2022.09.004_bb0165","doi-asserted-by":"crossref","first-page":"4608","DOI":"10.1002\/mp.12349","article-title":"Association between textural and morphological tumor indices on baseline PET-CT and early metabolic response on interim PET-CT in bulky malignant lymphomas","volume":"44","author":"Ben Bouall\u00e8gue","year":"2017","journal-title":"Med Phys"},{"issue":"10","key":"10.1016\/j.clinimag.2022.09.004_bb0170","doi-asserted-by":"crossref","first-page":"e467","DOI":"10.1016\/S2352-3026(16)30108-9","article-title":"The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, european, multicentre cohort study","volume":"3","author":"Agostinelli","year":"2016","journal-title":"Lancet Haematol"},{"issue":"3","key":"10.1016\/j.clinimag.2022.09.004_bb0175","doi-asserted-by":"crossref","first-page":"338","DOI":"10.2967\/jnumed.120.247924","article-title":"Comparison of interim PET response to second-line versus first-line treatment in classic hodgkin lymphoma: contribution to the development of response criteria for relapsed or progressive disease","volume":"62","author":"Kluge","year":"2021","journal-title":"J Nucl Med"},{"issue":"3","key":"10.1016\/j.clinimag.2022.09.004_bb0180","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1470-2045(15)70013-6","article-title":"PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study","volume":"16","author":"Moskowitz","year":"2015","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.clinimag.2022.09.004_bb0185","first-page":"5727","article-title":"The significance of PET\/CT in the initial staging of hodgkin lymphoma: experience outside clinical trials","volume":"37","author":"Angelopoulou","year":"2017","journal-title":"Anticancer Res"},{"issue":"1","key":"10.1016\/j.clinimag.2022.09.004_bb0190","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1182\/blood-2017-04-773838","article-title":"Reclassifying patients with early-stage Hodgkin lymphoma based on functional radiographic markers at presentation","volume":"131","author":"Akhtari","year":"2018","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clinimag.2022.09.004_bb0195","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2967\/jnumed.118.210047","article-title":"Metabolic tumor volume for response prediction in advanced-stage Hodgkin lymphoma","volume":"60","author":"Mettler","year":"2019","journal-title":"J Nucl Med"},{"issue":"13","key":"10.1016\/j.clinimag.2022.09.004_bb0200","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1182\/blood-2017-07-795476","article-title":"Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial","volume":"131","author":"Cottereau","year":"2018","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clinimag.2022.09.004_bb0205","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s00259-014-2705-y","article-title":"Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patients","volume":"41","author":"Meignan","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1016\/j.clinimag.2022.09.004_bb0210","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00259-009-1297-4","article-title":"FDG PET and PET\/CT: EANM procedure guidelines for tumour PET imaging: version 1.0","volume":"37","author":"Boellaard","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"10.1016\/j.clinimag.2022.09.004_bb0215","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.clml.2017.06.019","article-title":"How to approach a patient with limited stage hodgkin lymphoma who remains PET positive at the end of chemotherapy: radiation Therapy?Review","volume":"17","author":"Ozuah","year":"2017","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"10.1016\/j.clinimag.2022.09.004_bb0220","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.2147\/DDDT.S136988","article-title":"Lugano 2014 criteria for assessing FDG-PET\/CT in lymphoma: an operational approach for clinical trials","volume":"11","author":"Van Heertum","year":"2017","journal-title":"Drug Des Dev Ther"},{"issue":"1","key":"10.1016\/j.clinimag.2022.09.004_bb0225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s43055-020-00203-4","article-title":"Comparison between RECIST and PERCIST criteria in therapeutic response assessment in cases of lymphoma","volume":"51","author":"Tawfik","year":"2020","journal-title":"Egypt J Radiol Nucl Med"},{"issue":"2","key":"10.1016\/j.clinimag.2022.09.004_bb0230","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1148\/radiol.2016142043","article-title":"Practical PERCIST: a simplified guide to PET response criteria in solid tumors 1.0","volume":"280","author":"Joo Hyun","year":"2016","journal-title":"Radiology"}],"container-title":["Clinical Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0899707122002364?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0899707122002364?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T11:49:29Z","timestamp":1760269769000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0899707122002364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":46,"alternative-id":["S0899707122002364"],"URL":"https:\/\/doi.org\/10.1016\/j.clinimag.2022.09.004","relation":{},"ISSN":["0899-7071"],"issn-type":[{"value":"0899-7071","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"18F-FDG PET\/CT prognostic role in predicting response to salvage therapy in relapsed\/refractory Hodgkin's lymphoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Imaging","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinimag.2022.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}